Pioneering Study Indicates a Potential Treatment for Corneal Endothelial Disease, Reducing the Need for Corneal Transplants

Findings from a pioneering study opens in new tab/window in The American Journal of Pathology opens in new tab/window, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.  

Due to a lack of currently available medical therapy, patients suffering from corneal endothelial disease, which leads to corneal swelling and potentially blindness, commonly require corneal transplantation. In fact, corneal transplantation is the most common type of transplant performed. 

There is an urgent unmet need for safe and effective medical strategies for the prevention and reversal of persistent corneal edema, according to the investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology. Therefore, there is a pressing need for the development of efficacious treatment for preventing, and potentially reversing, corneal edema due to corneal endothelial cell (CenC) loss following corneal injury.  

This study examined the effect of local administration of α-MSH on persistent corneal edema and endothelial regeneration in an established model of injury-induced endothelial decompensation. The results show the impressive therapeutic potential of promoting the melanocortin pathway using α-MSH, thus opening new avenues of therapy. 

Lead investigator Reza Dana, MD, MSc, MPH, Director of the Cornea and Refractive Surgery Service at Mass Eye and Ear, and Claes H. Dohlman Professor of Ophthalmology at Harvard Medical School, explains, "Our data, demonstrating the potent therapeutic effects of α-MSH through melanocortin receptor agonism, provide compelling evidence for the therapeutic potential of this pathway for a wide array of ocular disorders such as Fuchs Dystrophy, a common disease and indication for corneal transplantation, as well as other disorders of the corneal endothelium that lead to corneal swelling."

α-MSH is an evolutionarily conserved neuropeptide derived from the proteolysis of the pro-opiomelanocortin and exerts an array of functions through different melanocortin receptors expressed in various tissues. Findings in this seminal study show that administration of α-MSH: 

• Prevents corneal endothelial cell death 

• Restores normal endothelial function 

• Permits the cornea to resume normal thickness after a severe injury that normally leads to corneal thickening 

• Causes corneal cells to regenerate 

Interventions to prevent corneal edema following ocular injury are currently limited to topical hypertonic saline and topical anti-inflammatory drugs. However, these interventions have limited efficacy, and they do not prevent CEnC decompensation.  

Dr. Dana concludes: "The findings of our study suggest the therapeutic potential of α-MSH, or analogs that work by activating the melanocortin receptor system, in management of pathologies where there is a risk of corneal endothelial dysfunction, such as corneal injury or intraocular surgery. This study outlines the critical role played by neuropeptides in CEnC maintenance and offers a novel perspective on their potential application in corneal endothelial regeneration."

Notes for editors 

The article is “The Neuropeptide α-Melanocyte–Stimulating Hormone Prevents Persistent Corneal Edema Following Injury,” by Hamid Alemi, Shudan Wang, Tomas Blanco, Francesca Kahale, Rohan B. Singh, Gustavo Ortiz, Aytan Musayeva, Erdem Yuksel, Kunpeng Pang, Neha Deshpande, Thomas H. Dohlman, Ula V. Jurkunas, Jia Yin, and Reza Dana (https://doi.org/10.1016/j.ajpath.2023.09.007 opens in new tab/window). It appears in The American Journal of Pathology, volume 194, issue 1 (January 2024), published by Elsevier opens in new tab/window. 

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(23)00363-2/fulltext opens in new tab/window. 

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] opens in new tab/window to request a PDF of the article or additional information. To request an interview with the authors please contact Ryan Jaslow, Program Director of External Communications, Mass General Brigham, at +1 617 573 4385 or [email protected] opens in new tab/window.  

This study was supported by the National Eye Institute/NIH grants T32EY007145, R21EY031759, and R21EY032695, R01EY012963, and core grant 5P30EY003790 (Schepens Eye Research Institute). 

About The American Journal of Pathology 

The American Journal of Pathology opens in new tab/window, official journal of the American Society for Investigative Pathology opens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.org opens in new tab/window 

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.